Skip to main content
Neuropsychiatric Disease and Treatment logoLink to Neuropsychiatric Disease and Treatment
. 2021 May 17;17:1481. doi: 10.2147/NDT.S316858

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]

PMCID: PMC8139728  PMID: 34040374

Barabássy Á, Sebe B, Acsai K, et al. Neuropsychiatr Dis Treat. 2021;17:957–970.

The authors have advised that there are errors in the first row of Table 5 on page 963.

Cariprazine 4.5 mg column, the value “1 (0.0)” should read “1 (0.2)”. Cariprazine 6 mg column, “2 (0.0)” should read “2 (0.3)”. Total 1.5-6 mg/d column, “0” should read “3 (0.1)”.

The authors apologize for these errors.


Articles from Neuropsychiatric Disease and Treatment are provided here courtesy of Dove Press

RESOURCES